Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback